# Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites

> **NCT03697668** · PHASE2 · UNKNOWN · sponsor: **Nurex S.r.l.** · enrollment: 50 (estimated)

## Conditions studied

- Plasmodium Falciparum Malaria (Drug Resistant)

## Interventions

- **DRUG:** Imatinib
- **DRUG:** Dihydroartemisinin-piperaquine

## Key facts

- **NCT ID:** NCT03697668
- **Lead sponsor:** Nurex S.r.l.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-09-17
- **Primary completion:** 2018-12-31
- **Final completion:** 2019-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2018-10-05

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03697668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03697668, "Triple Antimalarial Combination to Accelerate the Parasite Clearance and to Prevent the Selection of Resistant Parasites". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03697668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*